Cellular Therapy
News
FDA approves motixafortide for stem cell mobilization in myeloma
Motixafortide has been approved by the FDA to help mobilize hematopoietic stem cells in autologous transplants for patients with multiple myeloma...
Conference Coverage
Is additional treatment needed, pretransplant, for r/r AML?
The issue of whether or not patients with r/r AML require additional treatment pretransplant was debated at SOHO 2023.
Feature
‘Promising’ new txs for most common adult leukemia
The FDA has already approved these treatments for some other blood cancers, but chronic lymphocytic leukemia (CLL) poses unique challenges.
Conference Coverage
SCD, beta-thalassemia: CRISPR-based gene therapy `transformative’
Phase 3 results suggest potential for a “functional cure”; this treatment could become first-ever approved CRISPR gene-editing therapy.
From the Journals
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
Feature
Women hematologists advance MM research, give back
At the frontiers of CAR T-cell research for myeloma, women blood cancer specialists break new ground while also coaching their younger women...
Conference Coverage
CAR-T hikes overall survival in relapsed/refractory LBCL
Investigators say axi-cel should become the standard of care for second-line large B-cell lymphoma.
Conference Coverage
`Remarkable’: CAR T therapy for CLL/SLL
Primary analysis of the TRANSCEND CLL 004 trial showed that a single dose of CAR T therapy achieved durable responses in CLL and SLL, with a...
News
FDA approves new indication for avapritinib
Purported “first and only approved medicine” to treat adults with indolent systemic mastocytosis has been greenlit by the FDA.
News
FDA OKs stem cell therapy for blood cancer patients to reduce infection risks
Stem cell therapy approved by FDA for blood cancer patients aged 12 and older is aimed at reducing the risk of infections.